Pacer Advisors, Inc. C4 Therapeutics, Inc. Transaction History
Pacer Advisors, Inc.
- $38.6 Billion
- Q1 2024
A detailed history of Pacer Advisors, Inc. transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Pacer Advisors, Inc. holds 3,929 shares of CCCC stock, worth $18,151. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,929Holding current value
$18,151% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding CCCC
# of Institutions
111Shares Held
49.4MCall Options Held
455KPut Options Held
429K-
State Street Corp Boston, MA7.15MShares$33 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT4.33MShares$20 Million0.19% of portfolio
-
Commodore Capital LP New York, NY3.41MShares$15.8 Million2.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.92MShares$13.5 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.46MShares$11.4 Million1.64% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $226M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...